Drug therapy in the heart transplant recipient: part IV: drug-drug interactions.
Page
Robert L
RL
Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colo 80262, USA.
Miller
Geraldine G
GG
Lindenfeld
JoAnn
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D001692:Biological Transport; D001711:Biotransformation; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000890:Anti-Infective Agents; D000928:Antidepressive Agents; D002317:Cardiovascular Agents; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D003577:Cytochrome P-450 Enzyme System